<DOC>
	<DOCNO>NCT01796444</DOCNO>
	<brief_summary>The recently randomize trial ( ASCOG Z0011 ) support among patient limited sentinel lymph node ( SLN ) metastatic breast cancer treat breast conservation systemic therapy , use sentinel lymph node biopsy ( SLNB ) alone compare axillary lymph node dissection ( ALND ) result inferior survival . These patient , therefore , unlikely benefit surgery result longer period hospitalization , high cost higher postoperative morbidity . This result write 2012 National Comprehensive Cancer Network Clinical Practice Guidelines . However , Limitations Z0011 , failure achieve target accrual possible randomization imbalance favor SLNB-alone group , must consider . In hand , test different country need . The investigator design begin prospective randomize multicenter phase III study ALND vs. ALND breast Cancer positive SLN -- validation Z0011 China .</brief_summary>
	<brief_title>Axillary Lymph Node Dissection Versus Dissection Breast Cancer With Positive Sentinel Lymph Node</brief_title>
	<detailed_description>OBJECTIVES : To determine effect complete axillary lymph node dissection ( ALND ) survival patient sentinel lymph node ( SLN ) metastasis breast cancer . OUTLINE : This randomize multicenter study . Before randomization , woman stratify accord age ( ≤50 year , &gt; 50 year ) , tumor size ( ≤2cm , &gt; 2cm ) research center . All patient underwent lumpectomy sentinel lymph node biopsy ( SLNB ) . Eligible woman randomly assign ALND ALND Active Comparator : Patients undergo axillary lymph node dissection involve removal least level I II node . Experimental : No surgery axillary lymph node arm . All patient receive whole-breast oppose tangential-field radiation therapy . The use adjuvant systemic therapy determine treat physician accord recently NCCN . Patients follow every 4 month first 2 year , every 6 month third year fifth year , annually total 10 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female ; Patient age 18 year ; Patient histological proven invasive breast cancer ; Clinical T1T2 disease distant metastasis ; Patient clinical N0 status ; Patient conservative surgery sentinel lymph node ( SLN ) technique feasible start term carcinologic ; Patient positive SLNs 1~2 ; Signed consent participate . History neoadjuvant chemotherapy hormone therapy ; History breast cancer ( ipsilateral , i.e . recurrence , contralateral breast ) ; History invasive cancer ; Initial metastatic disease know ; Pregnant woman lactate woman ; Impossibility undergo medical examination study geographical , social psychological reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Sentinel Lymph Node Biopsy</keyword>
	<keyword>Axillary Lymph Node Dissection</keyword>
</DOC>